ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA MARKET ANALYSIS

Lymphomas are a type of cancer that affects lymphocytes which are further divided into two categories based on the type of cell into T-lymphocytes and B-lymphocytes. Angioimmunoblastic T-cell lymphoma (AITL) is rare form of non-Hodgkin lymphoma which effects the T-lymphocytes of lymphatic system. The AITL is characterised by transformation of T-lymphocytes into malignant cell which leads to enlargement of a specific lymph node region. The disease leads to dysfunction of the immune system, causing symptoms such as persistent fever, development of rash, weight loss, and tissue swelling among others. The major treatment for individuals suffering from AITL includes corticosteroids, single-agent chemotherapy, and multiagent chemotherapy.

The market is expected to witness lucrative growth over the forecast period owing to extensive research activities for studying new investigational therapies involving new medications and procedures for treatment of Angioimmunoblastic T-cell lymphoma (AITL). Several drugs have been tested in clinical trials such as Brentuximab vedotin, Lenalidomide, and Panobinostat which have shown promising results in the treatment of AITL. Hence, the high research & development activities and robust pipeline of drugs can be observed in the coming years, creating new opportunities for the growth of global angioimmunoblastic t-cell lymphoma market.

Global Angioimmunoblastic T-Cell Lymphoma Market- Dynamics

Key market players operating in the global angioimmunoblastic t-cell lymphoma market are receiving fast track approvals for their investigational drugs, which is expected to boost the market growth during the forecast period. For instance, in March 2020, Kura Oncology, Inc., a biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) granted fast track designation to the company’s leading drug tipifarnib for treating AITL patients. The drug is a potent, selective farnesyl transferase inhibitor which can be used as a monotherapy in relapsed or refractory AITL.

In addition, the growing number of research studies focused on evaluating new drugs and mechanism pathways is further driving the growth of global angioimmunoblastic t-cell lymphoma market. For instance, based on a May 2020, research study published in the American Association for Cancer Research, researchers conducted genomic studies in which they identified recurrent mutations in Ras homolog gene family, member A (RHOA) in around 50-70% individuals suffering with angioimmunoblastic t-cell lymphoma. Moreover, in the study they also showed the suppression of G17V RHOA by dasatinib, a multikinase inhibitor. Hence, the study concluded the targeting of TCR pathway for efficient development strategies against AITL.

Global Angioimmunoblastic T-Cell Lymphoma Market – Regional Insights

Among regions, North America holds dominant position in the global angioimmunoblastic t-cell lymphoma market during the forecast period. The major factor contributing in the market growth is majorly owing to high incidence of AITL in the region. For instance, according to the World Health Organization (WHO) 2017 revision, there are 29 distinct subtypes of peripheral T-cell lymphomas (PTCL) out of which the two most common forms are angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) accounting for an incidence of 1,800 and 2,500 cases per year in the U.S.

Asia Pacific is projected to grow with the fastest CAGR in the global angioimmunoblastic t-cell lymphoma market during the forecast period. The growth can be attributed to the extensive research taking place in the region. For instance, at the ESMO Asia Virtual Congress 2020, researchers discussed the treatment strategies for T-cell non-Hodgkin lymphomas (NHLs) by identification of the prevalence the subtypes, patient outcomes and available treatments across several Asian countries. This involved various multinational, multicentre prospective intercontinental registry studies conducted in research institutes situated in China, Indonesia, , Singapore, Taiwan and the Republic of Korea.

Global Angioimmunoblastic T-Cell Lymphoma Market – Taxonomy

By Drug:

• Azacitidine
• Brentuximab Vedotin
• Tipifarnib
• AUTO4
• MLN8237
• CD7-CART
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Global Angioimmunoblastic T-Cell Lymphoma Market – Competitive landscape

Key players operating in the global angioimmunoblastic t-cell lymphoma market include Bristol-Myers Squibb, Millennium Pharmaceuticals, Inc., Autolus Limited, Eisai Inc., Novartis, Kura Oncology, and PersonGen BioTherapeutics (Suzhou) Co., Ltd.